Tirzepatide is a novel synthetic peptide that functions as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique dual-incretin mechanism distinguishes tirzepatide from single-receptor agonists and has made it a subject of considerable interest in metabolic research.
In preclinical and mechanistic studies, tirzepatide demonstrates potent activity in modulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing food intake via central appetite pathways. Its dual receptor engagement is believed to produce synergistic effects on glycaemic control and energy balance beyond those achievable through GLP-1 receptor activation alone.
Researchers utilise tirzepatide to investigate type 2 diabetes pathophysiology, obesity-related metabolic dysfunction, insulin resistance, and the interplay between incretin hormones and adipose tissue remodelling. It is also studied in the context of non-alcoholic fatty liver disease (NAFLD) and cardiovascular metabolic risk markers.
Recommended storage: −20°C, protected from light and moisture. Reconstitute in sterile water or bacteriostatic water prior to use in research applications.
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.4 g/mol
Purity
>98%
CAS Number
2023788-19-2
Form
Lyophilised Powder
Research Applications
Metabolic syndrome research, Type 2 diabetes pathophysiology, Obesity and energy homeostasis, Insulin resistance modelling, NAFLD and hepatic lipid metabolism, Incretin hormone biology
For research purposes only. Not for human use. This product is intended solely for in vitro and preclinical research applications by qualified professionals.
Reviews
There are no reviews yet.